The development of rheumatology at the stage of formation of a new technological paradigm
Using rheumatology as an example, the paper considers current trends in the development of medical science in the 21st century. It is emphasized that biochemistry, genetics, and molecular biology are becoming the central research priority site attracting to clinical medicine and rheumatology, neur...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2019-11-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/2778 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850043047626145792 |
|---|---|
| author | T. V. Beketova |
| author_facet | T. V. Beketova |
| author_sort | T. V. Beketova |
| collection | DOAJ |
| description | Using rheumatology as an example, the paper considers current trends in the development of medical science in the 21st century. It is emphasized that biochemistry, genetics, and molecular biology are becoming the central research priority site attracting to clinical medicine and rheumatology, neuroscience (including cognitive and computational neurobiology, neuroinformatics), and psychology. Modern rheumatology effectively adapts current scientific achievements, which contributes to the significant progress of fundamental and clinical medicine. Deciphering the key immune mechanisms of the pathogenesis of immune-mediated inflammatory rheumatic diseases (IIRD) has allowed biotechnology techniques to be used to design fundamentally new drugs, such as biological agents, small molecules that are able to selectively affect certain pathogenetic constituents and to minimize the overall functioning of the immune system. This could substantially enhance the efficiency of treatment for IIRDs, by achieving a long-term stable remission in many patients and contributed to a significant expansion of ideas on human pathology. It is assumed that most promising studies of pharmacotherapy for IIRDs towards personalized medicine will be based on postgenomic technologies, including proteomics, transcriptomics, metabolomics, epigenomics, as well as the integrated use of digital methods. |
| format | Article |
| id | doaj-art-89e593ff09794f97901f7be756f188be |
| institution | DOAJ |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| publishDate | 2019-11-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj-art-89e593ff09794f97901f7be756f188be2025-08-20T02:55:20ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922019-11-0157549049510.14412/1995-4484-2019-490-4952530The development of rheumatology at the stage of formation of a new technological paradigmT. V. Beketova0V.A. Nasonova Research Institute of RheumatologyUsing rheumatology as an example, the paper considers current trends in the development of medical science in the 21st century. It is emphasized that biochemistry, genetics, and molecular biology are becoming the central research priority site attracting to clinical medicine and rheumatology, neuroscience (including cognitive and computational neurobiology, neuroinformatics), and psychology. Modern rheumatology effectively adapts current scientific achievements, which contributes to the significant progress of fundamental and clinical medicine. Deciphering the key immune mechanisms of the pathogenesis of immune-mediated inflammatory rheumatic diseases (IIRD) has allowed biotechnology techniques to be used to design fundamentally new drugs, such as biological agents, small molecules that are able to selectively affect certain pathogenetic constituents and to minimize the overall functioning of the immune system. This could substantially enhance the efficiency of treatment for IIRDs, by achieving a long-term stable remission in many patients and contributed to a significant expansion of ideas on human pathology. It is assumed that most promising studies of pharmacotherapy for IIRDs towards personalized medicine will be based on postgenomic technologies, including proteomics, transcriptomics, metabolomics, epigenomics, as well as the integrated use of digital methods.https://rsp.mediar-press.net/rsp/article/view/2778immune-mediated inflammatory rheumatic diseasespersonalized medicinebiological agents |
| spellingShingle | T. V. Beketova The development of rheumatology at the stage of formation of a new technological paradigm Научно-практическая ревматология immune-mediated inflammatory rheumatic diseases personalized medicine biological agents |
| title | The development of rheumatology at the stage of formation of a new technological paradigm |
| title_full | The development of rheumatology at the stage of formation of a new technological paradigm |
| title_fullStr | The development of rheumatology at the stage of formation of a new technological paradigm |
| title_full_unstemmed | The development of rheumatology at the stage of formation of a new technological paradigm |
| title_short | The development of rheumatology at the stage of formation of a new technological paradigm |
| title_sort | development of rheumatology at the stage of formation of a new technological paradigm |
| topic | immune-mediated inflammatory rheumatic diseases personalized medicine biological agents |
| url | https://rsp.mediar-press.net/rsp/article/view/2778 |
| work_keys_str_mv | AT tvbeketova thedevelopmentofrheumatologyatthestageofformationofanewtechnologicalparadigm AT tvbeketova developmentofrheumatologyatthestageofformationofanewtechnologicalparadigm |